Effective response to immune checkpoint inhibitors depends on the proliferation and expansion of tumor-reactive CD8+ T cells. By combining analysis of CD8+ T cell clones in a preclinical multi-site tumor model with clinical datasets, the authors track the expansion dynamics of hundreds of T cell clones over time and define a signature to predict intratumoral CD8+ T cell expansion in response to immunotherapies.
- Munetomo Takahashi
- Mikiya Tsunoda
- Satoshi Ueha
